Komal Jhaveri, MD, Memorial Sloan Kettering Cancer Center and lead author of the EMBER-3 trial, as she discusses the significance of this approval, its impact on the treatment…
Sung-Bae Kim, MD, PhD, Asan Medical Center, Seoul, South Korea, reports on results from the East Asian subgroup of the Phase 3 EMBER‑3 trial, showing that in patients…
David M. Cognetti, MD, Assistant Professor of Otolaryngology – Head and Neck Surgery at Jefferson Medical College, discusses optimal care for head and neck cancer patients. Sponsored by…
NEW YORK (Reuters Health) – High blood pressure accounts for some of the disproportionately higher mortality rates among African American patients with breast cancer compared with Caucasian patients,…
NEW YORK (Reuters Health) – An analysis of data from the Health Professionals Follow-up Study confirms that men with diabetes mellitus are less prone to develop prostate cancer…
NEW YORK (Reuters Health) – When radical cystectomy is not performed within 12 weeks of diagnosis with stage II bladder cancer, all-cause and disease-specific mortality increases, US researchers…
Jaime Landman MD, Director of Minimally Invasive Urology at Columbia Medical Center discusses Cytoreductive Nephrectomy, the cutting edge of kidney cancer management for patients whose disease is not…
NEW YORK (Reuters Health) – Men ages 75 to 80 years old with a prostate specific antigen (PSA) level less than 3 ng/mL are unlikely to experience life-threatening…
NEW YORK (Reuters Health) – In older prostate cancer patients with a biochemical recurrence, cancer anxiety predicts earlier use of androgen deprivation therapy (ADT), new research shows. This…
NEW YORK (Reuters Health) – Although it is safe, low-dose vitamin K used to treat warfarin recipients with high INRs (international normalized ratios) does not reduce episodes of…
NEW YORK (Reuters Health) – New evidence indicates that elevated serum levels of ionized calcium may predict the risk of death from prostate cancer. If verified in future…
NEW YORK (Reuters Health) – In a phase I trial involving patients with advanced squamous cell carcinoma of the head and neck (SCCHN), direct intratumoral injection of epithelial…
